Hsbc Holdings PLC Increases Stock Holdings in Zoetis Inc. $ZTS

Hsbc Holdings PLC raised its stake in shares of Zoetis Inc. (NYSE:ZTS) by 18.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,324,110 shares of the company’s stock after purchasing an additional 209,897 shares during the quarter. Hsbc Holdings PLC’s holdings in Zoetis were worth $166,585,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Employees Provident Fund Board purchased a new stake in Zoetis in the fourth quarter worth about $193,402,000. EJMK Ventures LLC bought a new stake in Zoetis during the 4th quarter valued at approximately $250,000. Reflection Asset Management purchased a new position in shares of Zoetis during the 4th quarter worth approximately $54,000. MidFirst Bank bought a new position in shares of Zoetis in the 4th quarter worth approximately $633,000. Finally, Pacer Advisors Inc. raised its position in shares of Zoetis by 18.3% in the 4th quarter. Pacer Advisors Inc. now owns 141,883 shares of the company’s stock worth $17,852,000 after acquiring an additional 21,964 shares in the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on ZTS. Leerink Partners restated a “market perform” rating on shares of Zoetis in a research note on Tuesday, March 10th. Stifel Nicolaus reduced their price target on Zoetis from $105.00 to $95.00 and set a “hold” rating on the stock in a research note on Friday, May 22nd. Argus reiterated a “hold” rating on shares of Zoetis in a report on Wednesday, May 27th. Citigroup lowered their price objective on Zoetis from $145.00 to $112.00 and set a “buy” rating for the company in a research report on Monday, May 18th. Finally, UBS Group reduced their target price on shares of Zoetis from $130.00 to $99.00 and set a “neutral” rating on the stock in a research report on Friday, May 8th. Six investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Zoetis currently has a consensus rating of “Hold” and a consensus target price of $133.92.

Key Stories Impacting Zoetis

Here are the key news stories impacting Zoetis this week:

• Negative Sentiment: Multiple law firms, including Rosen, The Gross Law Firm, Kessler Topaz, Bragar Eagel & Squire, and others, announced or reiterated securities class actions against Zoetis, with claims tied to alleged misstatements and omissions about product adoption during the January 14, 2025 to May 6, 2026 period. Article Title
• Negative Sentiment: The lawsuits highlighted a July 27, 2026 lead-plaintiff deadline and suggested investors who bought ZTS during the class period may have suffered losses, increasing legal overhang and uncertainty for the stock. Article Title
• Neutral Sentiment: Zacks noted ZTS recently outperformed the broader market, but that commentary was largely backward-looking and did not change the heavier focus on litigation headlines. Article Title

Insider Activity

In related news, Director Frank A. Damelio purchased 6,650 shares of Zoetis stock in a transaction dated Wednesday, May 13th. The stock was purchased at an average cost of $75.39 per share, for a total transaction of $501,343.50. Following the completion of the acquisition, the director directly owned 21,458 shares of the company’s stock, valued at $1,617,718.62. The trade was a 44.91% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Michael B. Mccallister purchased 3,000 shares of the stock in a transaction dated Monday, May 11th. The stock was bought at an average cost of $77.76 per share, with a total value of $233,280.00. Following the transaction, the director owned 24,524 shares in the company, valued at $1,906,986.24. The trade was a 13.94% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders purchased 11,650 shares of company stock worth $886,384 over the last three months. 0.22% of the stock is currently owned by corporate insiders.

Zoetis Stock Performance

Shares of ZTS opened at $78.69 on Friday. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80. The stock has a market cap of $32.99 billion, a P/E ratio of 13.05, a P/E/G ratio of 1.23 and a beta of 0.75. The business’s 50 day moving average price is $93.01 and its 200-day moving average price is $112.54. Zoetis Inc. has a 52 week low of $72.38 and a 52 week high of $161.77.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The company had revenue of $2.26 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The firm’s quarterly revenue was up 2.9% on a year-over-year basis. During the same period last year, the business earned $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Equities research analysts anticipate that Zoetis Inc. will post 6.88 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be paid a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s dividend payout ratio is currently 35.16%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.